ObjectiveTo study the therapeutic effect and safety of voriconazole prevention and cure on invasive fungal infection (IFI) in patients with hematological malignancy.MethodsSeventy-six patients with hematological malignancy were divided into observation group (39 cases) and control group (37 cases) by random digits table.The control group was given voriconazole of intravenous drip.The observation group was given voriconazole of intravenous drip sequence oral administration.The rates of occur IFI and adverse effect were compared between the two groups.ResultsIn observation group and control group,the confirmed diagnose rates were 17.9％(7/39) and 18.9％(7/37),clinical diagnose rates were 23.1％(9/39)and 27.0％ (10/37),para-diagnose rates were 59.0％(23/39) and 54.1％(20/37),there was no significant difference between the two groups(P＞ 0.05).In observation group and control group,the paropsia rates were 12.8％(5/39) and 21.6％(8/37),transaminase elevated rates were 12.8％(5/39) and 43.2％( 16/37),there were significant differences between the two groups(P ＜ 0.05 ).ConclusionThe voriconazole of intravenous drip sequence oral administration and intravenous drip has a nice effect to IFI,and intravenous drip sequence oral administration could reduce the adverse effect.

Objective To explore the expressions and clinical significances of deleted in liver cancer-1 (DLC-1 ) and Rho associated coiledcoil forming protein kinase (ROCK )Ⅰ in non-small lung cancer (NSCLC).Methods The expressions of DLC-1 and ROCKⅠ in NSCLC and adjacent tissue of 48 patients with pathologically confirmed as NSCLC and undergone surgical resection were detected by immunohistochemis-try EnVision method.The correlations among DLC-1 protein,ROCKⅠ protein and the clinical pathological characteristics were analyzed.The prognostic value of DLC-1 in patients with NSCLC was studied.Results The expression of DLC-1 protein in NSCLC tissue was low or missing,and the positive rate was 33.3%(16/48),significantly lower than that in the tissue adjacent to carcinoma 70.8% (34/48),with statistical significance (χ2 =13.523,P<0.01).The positive expression rate of ROCKⅠprotein in NSCLC was 58.3%(28/48),higher than that of tissue adjacent to carcinoma 0(0/48),with statistical significance (χ2 =39.529, P<0.01).The expression of DLC-1 protein was correlated with tumor differentiation,lymph node metastasis and clinical stage,rather than with sex,smoking history and organization type.Through the correlation analy-sis,the expression of ROCKⅠin DLC-1 positive group was 37.5%(6/16),and the expression rate of ROCKⅠ in DLC-1 negative group was 68.8%(22/32).There was negative correlation between DLC-1 and ROCKⅠin NSCLC tissues (r=-2.214,P=0.039).The 3 year survival rate in DLC-1 protein high expression group was obviously higher than that in low expression group,with statistical significance (P=0.043).Conclusion Low or missing expression of DLC-1 and high expression of ROCKⅠ protein may play an important role in the occurrence and development of NSCLC.Detecting the expression of DLC-1 and ROCKⅠprotein may be useful for evaluating the biological behavior and prognosis of NSCLC.

The development of non-small cell lung cancer (NSCLC) is a complex process which referring to multi-factor interaction.In this process,p53 gene regulates the normal growth of cells,but p53 gene after mutation can induce the occurrence of NSCLC,promote tumor distant metastasis,induce chemotherapy resistance,and cause poor prognosis of patients.Therefore,the restoration of normal expression of p53 gene is very significant for the treatment of NSCLC.In recent years,the rapid progress of p53 gene therapy has opened up a new way for the treatment of NSCLC.

At present,the treatment of non-small cell lung cancer (NSCLC) has entered the era of targeted therapy,and small molecule tyrosine kinase inhibitors are typical representatives,which have clear molecular targets and remarkable effects.But many patients without mutations are not able to benefit from them.Vascular endothelial growth factor and immune targeted therapy have become the new focus of NSCLC treatment.Inhibitors such as programmed cell death-1 and programmed cell death-ligand 1 have shown great applied potential in a series of clinical trials of NSCLC.

Circulating microRNAs (miRNAs) are closely related to the occurrence and development of multiple myeloma (MM).miRNAs play a significant role in early prediction,disease diagnosis,prognosis evaluation,progress monitoring and assessment of drug resistance of MM.As important biologic tumor markers,miRNAs are expected to become new targets for the diagnosis and treatment of MM.